Joost G E Janzing
Overview
Explore the profile of Joost G E Janzing including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
206
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Sathyanarayanan A, Mueller T, Moni M, Schueler K, Baune B, Dierssen M, et al.
Eur Neuropsychopharmacol
. 2023 Jan;
69:26-46.
PMID: 36706689
To study mental illness and health, in the past researchers have often broken down their complexity into individual subsystems (e.g., genomics, transcriptomics, proteomics, clinical data) and explored the components independently....
12.
Ter Hark S, Vos C, Aarnoutse R, Schene A, Coenen M, Janzing J
J Psychiatr Res
. 2022 Apr;
150:202-213.
PMID: 35397333
Tricyclic antidepressants (TCAs) are frequently prescribed in case of non-response to first-line antidepressants in Major Depressive Disorder (MDD). Treatment of MDD often entails a trial-and-error process of finding a suitable...
13.
Meerman J, Ter Hark S, Janzing J, Coenen M
J Affect Disord
. 2022 Feb;
304:1-11.
PMID: 35151671
Background: Understanding the genetic underpinnings of antidepressant treatment response in unipolar major depressive disorder (MDD) can be useful in identifying patients at risk for poor treatment response or treatment resistant...
14.
Vos C, Aarnoutse R, Op de Coul M, Spijker J, Groothedde-Kuyvenhoven M, Mihaescu R, et al.
BMC Psychiatry
. 2021 Oct;
21(1):481.
PMID: 34598683
Background: Traditionally tricyclic antidepressants (TCAs) have an important place in treatment of major depressive disorder (MDD). Today, often other antidepressant medications are considered as first step in the pharmacological treatment...
15.
Vos C, Birkenhager T, Nolen W, Van den Broek W, Coenen M, Ter Hark S, et al.
Brain Behav Immun Health
. 2021 Aug;
16:100319.
PMID: 34423321
Background: Low-grade inflammation occurs in a subgroup of patients with Major Depressive Disorder (MDD) and may be associated with response to antidepressant medications. The Neutrophil to Lymphocyte Ratio (NLR) and...
16.
Janzing J, Birkenhager T, Van den Broek W, Breteler L, Nolen W, Verkes R
J Psychiatr Res
. 2020 Sep;
130:321-326.
PMID: 32877825
Background: Psychomotor Retardation is a key symptom of Major Depressive Disorder. According to the literature its presence may affect the prognosis of treatment. Aim of the present study is to...
17.
Sluiter R, Janzing J, van der Wilt G, Kievit W, Teichert M
Pharmacogenomics J
. 2019 Jan;
19(5):480-489.
PMID: 30647446
The pharmacokinetics of many antidepressants (tricyclic antidepressants (TCA) or selective serotonin re-uptake inhibitors (SSRI)) are influenced by the highly polymorphic CYP2D6 enzyme. Therefore, pharmacogenetics could play an important role in...
18.
van Esch A, Fest A, Hoffland B, Janzing J, Steens S, Esselink R, et al.
J Addict Med
. 2018 Nov;
13(3):241-244.
PMID: 30394993
Introduction: Catatonia is a syndrome that can present in different forms and can occur in multiple psychiatric and somatic conditions. This case report describes lethal catatonia caused by delayed toxic...
19.
de Boer A, Vermeulen K, Egger J, Janzing J, de Leeuw N, Veenstra-Knol H, et al.
Mol Autism
. 2018 Feb;
9:5.
PMID: 29416845
Background: Genetic mosaicism is only detected occasionally when there are no obvious health or developmental issues. Most cases concern healthy parents in whom mosaicism is identified upon targeted testing of...
20.
Vermeulen K, Egger J, Janzing J, Van Dongen L, van Bokhoven H, Kleefstra T, et al.
J Am Acad Child Adolesc Psychiatry
. 2017 Jun;
56(7):618-619.
PMID: 28647014
No abstract available.